key: cord-0289068-29te5wze authors: Alexandre, Marie; Marlin, Romain; Prague, Mélanie; Coleon, Séverin; Kahlaoui, Nidhal; Cardinaud, Sylvain; Naninck, Thibaut; Delache, Benoit; Surenaud, Mathieu; Galhaut, Mathilde; Dereuddre-Bosquet, Nathalie; Cavarelli, Mariangela; Maisonnasse, Pauline; Centlivre, Mireille; Lacabaratz, Christine; Wiedemann, Aurelie; Zurawski, Sandra; Zurawski, Gerard; Schwartz, Olivier; Sanders, Rogier W; Le Grand, Roger; Levy, Yves; Thiébaut, Rodolphe title: SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccines date: 2021-11-01 journal: bioRxiv DOI: 10.1101/2021.10.29.466418 sha: 1fc8241862745c982c5795126dab8d9a294180b5 doc_id: 289068 cord_uid: 29te5wze The definition of correlates of protection is critical for the development of next generation SARS-CoV-2 vaccine platforms. Here, we propose a new framework for identifying mechanistic correlates of protection based on mathematical modelling of viral dynamics and data mining of immunological markers. The application to three different studies in non-human primates evaluating SARS-CoV-2 vaccines based on CD40-targeting, two-component spike nanoparticle and mRNA 1273 identifies and quantifies two main mechanisms that are a decrease of rate of cell infection and an increase in clearance of infected cells. Inhibition of RBD binding to ACE2 appears to be a robust mechanistic correlate of protection across the three vaccine platforms although not capturing the whole biological vaccine effect. The model shows that RBD/ACE2 binding inhibition represents a strong mechanism of protection which required significant reduction in blocking potency to effectively compromise the control of viral replication. One Sentence Summary A framework for modelling the immune control of viral dynamics is applied to quantify the effect of several SARS-CoV-2 vaccine platforms and to define mechanistic correlates of protection. RBD/ACE2 binding inhibition represents a strong mechanism of protection which required 48 significant reduction in blocking potency to effectively compromise the control of viral 49 replication. 52 There is an unprecedented effort for SARS-CoV-2 vaccine development with 294 candidates 53 currently evaluated (1). However, variants of concern have emerged before the vaccine coverage 54 was large enough to control the pandemics (2). Despite a high rate of vaccine protection, these 55 variants might compromise the efficacy of current vaccines (3-6). Control of the epidemic by 56 mass vaccination may also be compromised by unknown factors such as long-term protection 57 and the need of booster injections in fragile, immuno-compromised, elderly populations, or even 58 for any individual if protective antibody levels wane. Furthermore, the repeated use of some of 59 the currently approved vaccine could be compromised by potential adverse events or by 60 immunity against vaccine viral vectors (7). Finally, the necessity to produce the billions of doses 61 required to vaccinate the world's population also explains the need to develop additional vaccine 62 candidates. 63 The identification of correlates of protection (CoP) is essential to accelerate the development of captured the observed variation of the dynamics of viral load. The variation of those parameters 140 could be partly explained by the group to which the animals belong reducing the unexplained 141 variability of the cell infectivity by 66% and of the loss rate of infected cells by 54% (Table S1 ). 142 The model fitted well the observed dynamics of gRNA and sgRNA ( Figure 2B ). the group of intervention, reducing the unexplained variability by 87% compared to 66% (Table 181 S1 ). The marker actually takes into account the variation between animals within the same 182 group. Hence, it suggests that the levels of anti-RBD antibodies induced by the vaccine that 183 block attachment to ACE2 are highly efficient at reflecting the neutralization of new infections in 184 vivo. Furthermore, when taking into account the information provided by the RBD-ACE2 185 binding inhibition assay, the effect of the group of intervention was no longer significant (Table S1 ). Finally, we looked at the estimated infection rate according to the inhibition binding assay 187 in every animal ( Figure 4C) . The values were not overlapping at all, distinguishing clearly the 188 vaccinated and unvaccinated animals. 189 190 In the next step, several markers (IgG binding anti-RBD antibodies, CD8 + T cells producing IgG anti-RBD binding antibodies (the higher the better) led to R>1, whereas in vaccinated 215 animals, the value of ECL RBD led to R<1. Therefore, our modeling study shows that the 216 inhibition of binding of RBD to ACE2 by antibodies is sufficient to control initial infection of 217 the host ( Figure 4E ). According to the observed value of ECL RBD in vaccinated animals (e.g., 218 66 AU in Figure 4E ), a decrease of more than 2 log10 of the inhibition capacity (to reach 81 000 219 AU), due to variant of concern (VoC) or waning of immunity, would have been necessary to Figure S8E ). 246 Finally, we applied our approach to a published NHP study performed to evaluate several doses 247 of mRNA-1273 vaccine (24) . Using available data, we compared the viral dynamics in the 100 248 µg, 10 µg and placebo group. We started from the same model as defined previously. We 249 estimated a reduction of transmission rate by 97% but we did not find any additional effect. The next question after determining which marker is a valid mCoP is to define the concentration 285 that leads to protection, looking for a threshold effect that will help to define an objective (10, The MSD pseudo-neutralization assay was used to measure antibodies neutralizing the binding 388 of the spike protein to the ACE2 receptor. Plates were blocked and washed as above, assay Consideration of the volume of distribution"). Each animal was exposed to 1x10 6 pfu of SARS-420 CoV-2 representing 2.19x10 10 virions. Over the total inoculum injected (5 mL), 10% (0.5 mL) 421 and 90% (4.5 mL) of virions were respectively injected by the intra-nasal route and the intra-422 tracheal route leading to the following initial concentrations of the incoculm within each 423 compartment : , with Inoc 0 the number virions injected via 424 the inoculum. 425 Using the gRNA and sgRNA viral loads, we estimated the viral infectivity, the viral production 426 rate and the loss rate of infected cells (Table S2) . To account for inter-individual variability and 427 covariates, each of those three parameters was described by a mixed-effect model and jointly 428 estimated between the two compartments as follows: where Θ is the set of parameters of the subject i for the compartment X and ε are the additive 442 normally distributed measurement errors. The possibility for viruses to migrate from nasopharyngeal to tracheal compartment and vice 509 versa was tested. To this end, equations of infectious (V i ) and non-infectious (V ni ) viruses in 510 equation (1) between the two compartments were linked as follows: with the arrow symbolizing the modification of the equations defined in (1) and where g TN and 512 g NT are the positive constant rates of exchange from trachea to nasopharynx and vice versa, 513 respectively. Data described in the main article were too much sparse to estimate either 514 bidirectional or at least one of the two unidirectional transfers defined by g TN and g NT , additional 515 data were used. Two naive macaques were exposed to the same dose (1x10 6 pfu) of SARS-CoV-516 2 than our 18 monkeys but were inoculated via intra-gastric route (4.5mL) instead of intra-517 tracheal route. Similarly to our study, the viral gRNA dynamics in both tracheal and 518 nasopharyngeal compartments were repeatedly measured during the 20 days following the 519 challenge ( Figure S9E) . The model resulting from equation (5) was used to fit these data, 520 considering all parameters as fixed (see Table S2 ), except for g TN After identifying the effect of the group of intervention on both the viral infectivity (β) and the 531 loss rate of infected cells (δ), we aimed at determining whether some immunological markers quantified in the study could capture this effect. To this end, we developed a classic stepwise 533 data-driven automatic covariate modelling method ( Figure S10) . The specificity of this method 534 is the possibility to add either time-dependent or constant covariates in the model. 535 At the initialization step (k=0) (see Figure S10) Induced Protection against SARS-CoV-2 Immunological surrogate endpoints of COVID-2019 629 vaccines: the evidence we have versus the evidence we need., Signal transduction and targeted 630 therapy Neutralizing antibody levels are highly 633 predictive of immune protection from symptomatic SARS-CoV-2 infection DNA vaccine protection against SARS-CoV-2 in rhesus macaques Evidence for antibody as a protective correlate for COVID-19 vaccines Correlates of 650 protection against symptomatic and asymptomatic SARS-CoV-2 infection, medRxiv Rapid isolation and profiling of a diverse panel of 657 human monoclonal antibodies targeting the SARS-CoV-2 spike protein Single-shot Ad26 vaccine protects against SARS-669 CoV-2 in rhesus macaques A single 675 dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and 676 T cell responses Correlates of protection against SARS-CoV-2 in rhesus macaques Complex correlates of protection after vaccination Updates on immunologic correlates of vaccine-induced protection Correlates of immunity to filovirus infection Approaches and Challenges in SARS-CoV-2 Vaccine 690 Animal models for COVID-19 How to test SARS-CoV-2 vaccines ethically even after one is 703 available Evaluation of the mRNA-1273 Vaccine 716 against SARS-CoV-2 in Nonhuman Primates Nomenclature for immune correlates of protection after 719 vaccination Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load A quantitative model 727 used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides 728 insights into the pathogenesis and treatment of SARS-CoV-2 SARS-CoV-2 734 viral dynamics in non-human primates Modeling the viral dynamics of 736 SARS-CoV-2 infection Noncovalent assembly of anti-dendritic cell 746 antibodies and antigens for evoking immune responses in vitro and in vivo Superiority in Rhesus 752 Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with 753 Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell 754 Responses TLR3 agonist and CD40-targeting 757 vaccination induces immune responses and reduces HIV-1 reservoirs TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized 763 mice Kinetics of Influenza A Virus Infection in Humans SARS-CoV-2 infection induces the dedifferentiation of 770 multiciliated cells and impairs mucociliary clearance Two-component spike nanoparticle vaccine protects 779 macaques from SARS-CoV-2 infection Dissecting Polyclonal Vaccine-Induced Humoral Immunity 784 against HIV Using Systems Serology Asymptomatic and 788 symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 795 variants in humans Immunological surrogate endpoints of COVID-2019 797 vaccines: the evidence we have versus the evidence we need., Signal transduction and targeted 798 therapy COVID-19 Genomics UK consortium Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 810 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial SARS-CoV-2 infection protects against rechallenge in 820 rhesus macaques Transmission of COVID-19 in 282 clusters in Catalonia, Spain: 828 a cohort study Cohort Study groups, Modeling SARS-CoV-2 viral kinetics and association with mortality in 835 hospitalized patients from the French COVID cohort SARS-CoV-2 RNAemia and proteomic trajectories inform 843 prognostication in COVID-19 patients admitted to intensive care Viral load 848 dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province Concerns about SARS-CoV-2 evolution 852 should not hold back efforts to expand vaccination Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by 868 convalescent and vaccine sera Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by 873 COVID-19 Genomics UK (COG-UK) SARS-CoV-2 within-host diversity and transmission SARS-CoV-2 evolution in 885 an immunocompromised host reveals shared neutralization escape mechanisms Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant RTS,S 901 Vaccine Evaluation Group, Randomized, double-blind, phase 2a trial of falciparum malaria 902 vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and 903 immunologic associates of protection A molecular cell atlas of the human lung from single-907 cell RNA sequencing A guide to vaccinology: from basic principles to new 909 developments Using vaccine Immunostimulation/Immunodynamic modelling methods to 912 inform vaccine dose decision-making 919 Evolution of antibody immunity to SARS-CoV-2 Kinetics and correlates of the neutralizing 924 antibody response to SARS-CoV-2 infection in humans Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses 929 Impact the Estimates of Infections in Population-Based Seroprevalence Studies Evaluation of a novel multiplexed assay for determining IgG levels 933 and functional activity to SARS-CoV-2 Development of a rhesus monkey 937 lung geometry model and application to particle deposition in comparison to humans the model definition Dodan for the NHP experiments Morin for the RT-qPCR, ELISpot and Luminex 944 assays, and for the preparation of reagents Fert for her help with the CT scans Guyon for the NHP sample processing Keyser for the transports organization Gorin for their help with the logistics and safety management; I. Mangeot for 948 here help with resources management and B. Targat contributed to data management. The 949 monkey and syringe pictures in Fig.1 was created with BioRender.com. This work was supported 950 by INSERM and the Investissements d'Avenir program, Vaccine Research Institute (VRI), 951 managed by the ANR under reference Programme Investissements d'Avenir", managed by the ANR 954 under reference ANR-11-INBS-0008. The Fondation Bettencourt Schueller and the Region Ile-955 de-France contributed to the implementation of IDMIT's facilities and imaging technologies 956 used to define volume of respiratory tract. The NHP study We thank Lixoft 958 SAS for their support MP 970 Writing -Review & Editing: All 971 Visualization: MA, RM, NK, TN, MP 972 Supervision: RT, RLG, YL, MP 973 Project administration: RT, RLG, YL 974 Funding acquisition: RT, RLG 1001 tracheal (bottom) compartments after the initial exposure to SARS-CoV-2 in naive macaques 1002 (black, right) and after the second exposure in convalescent (blue, middle) and vaccinated (green, 1003 left) animals. Solid thin lines indicate individual dynamics predicted by the model adjusted on 1004 the effect of group. Thick dashed lines indicate mean viral loads over time convalescent (blue, dashed lines) and vaccinated (green, dotted lines) animals: target cells 1008 as percentage of the value at the challenge (top, left), infected cells (top, middle), productively 1009 infected cells (top, right), inoculum (bottom, right), infectious (bottom, left) and non-infectious 1010 virus (bottom, middle) We would like to thank J. Guedj and O. Terrier for fruitful discussions on 941 Authors declare that they have no competing interests